Therapeutic landscape and future direction of metastatic colorectal cancer

Hideaki Bando,Atsushi Ohtsu,Takayuki Yoshino

DOI: https://doi.org/10.1038/s41575-022-00736-1

2023-01-22

Abstract:In the era of targeted therapy based on genomic alterations, the treatment strategy for metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment initiation, determination of tumour genomic status for KRAS and NRAS , BRAF V600E mutations, ERBB2 , and microsatellite instability and/or mismatch repair (MMR) status is recommended. In patients with deficient MMR and BRAF V600E mCRC, randomized phase III trials have established the efficacy of pembrolizumab as first-line therapy and the combination of encorafenib and cetuximab as second-line or third-line therapy. In addition, new agents have been actively developed in other rare molecular fractions such as ERBB2 alterations and KRAS G12C mutations. In March 2022, the combination of pertuzumab and trastuzumab for ERBB2-positive mCRC was approved in Japan, thereby combining real-world evidence from the SCRUM-Japan Registry. As the populations are highly fragmented owing to rare genomic alterations, various strategies in clinical development are expected. Clinical development of a tumour-agnostic approach, such as NTRK fusion and tumour mutational burden, has successfully introduced corresponding drugs to clinical practice. Considering the difficulty of randomized trials owing to cost–benefit and rarity, a promising solution could be real-world evidence utilized as an external control from the molecular-based disease registry.

gastroenterology & hepatology